MG
HEPA

Michael Gelband’s Hepion Pharmaceuticals HEPA Stock Holding History

Michael Gelband’s Portfolio HEPA Stock Details HEPA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-24
Closed -$28K – 2375
2021
Q4 		$28K Sell
24
-13
-35% -$17.8K ﹤0.01% 2073
2021
Q3 		$56K Buy
37
+15
+68% +$24K ﹤0.01% 1965
2021
Q2 		$44K Buy
+22
New +$40.3K ﹤0.01% 2231
2020
Q4 		– Sell
-12
Closed -$36K – 2119
2020
Q3 		$36K Buy
+12
New +$43.1K ﹤0.01% 1647

Other funds holding HEPA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
ML
McAdam LLC Philadelphia, Pennsylvania $2.59B AUM 21.24% 1-Year Est. Return

Michael Gelband's HEPA Position: Q1 2022 in Review

Michael Gelband sold out of Hepion Pharmaceuticals (HEPA) in Q1 2022, closing a stake of 24 shares — an estimated $28K sold.

Michael Gelband first reported a position in HEPA in Q3 2020 and held it in 4 quarters. The position peaked at $56K in Q3 2021. 31 funds tracked by Wall St. Rank hold HEPA as of Q1 2022.

  • Michael Gelband reported no remaining Hepion Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Michael Gelband sold 24 Hepion Pharmaceuticals shares in Q1 2022, an estimated $28K.
  • Michael Gelband first reported a position in Hepion Pharmaceuticals in Q3 2020 and held it in 4 quarters.
  • Michael Gelband's Hepion Pharmaceuticals position peaked at $56K in Q3 2021.
  • 31 funds tracked by Wall St. Rank held Hepion Pharmaceuticals as of Q1 2022.

Based on ExodusPoint Capital Management's 13F filing for Q1 2022, filed 13 May 2022.